ZURA

Zura Bio Ltd

12 filings tracked

healthcarebiotechnologySMALL ($300M-2B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

neutralMay 22

Resignation of director Someit Sidhu without reported disagreement.

management change

30%

neutralMay 22

Resignation of director Someit Sidhu without reported disagreement.

management change

30%

neutralMay 22

Resignation of director Someit Sidhu without reported disagreement.

management change

30%

neutralMay 22

Resignation of director Someit Sidhu without reported disagreement.

management change

30%

neutralMay 22

Resignation of director Someit Sidhu without reported disagreement.

management change

30%

neutralMay 22

Resignation of director Someit Sidhu without reported disagreement.

management change

30%

bullishMay 7

Raised $134.6M in February 2026, extending runway through 2028.

capital raise

90%

bearishMay 7

Net loss widened by 39% to $24.2M in the first quarter.

earnings miss

60%

bearishMay 7

Operating cash burn increased 71% year-over-year to $18.9M.

margin compression

70%

bearishMay 7

Significant increase in share count from 73.7M to 94.9M plus warrants.

dilution risk

80%

bullishMay 7

Raised $134.6M in February 2026, extending runway through 2028.

capital raise

90%

bearishMay 7

Net loss widened by 39% to $24.2M in the first quarter.

earnings miss

60%

bearishMay 7

Operating cash burn increased 71% year-over-year to $18.9M.

margin compression

70%

bearishMay 7

Significant increase in share count from 73.7M to 94.9M plus warrants.

dilution risk

80%

bullishMay 7

Raised $134.6M in February 2026, extending runway through 2028.

capital raise

90%

bearishMay 7

Net loss widened by 39% to $24.2M in the first quarter.

earnings miss

60%

bearishMay 7

Operating cash burn increased 71% year-over-year to $18.9M.

margin compression

70%

bearishMay 7

Significant increase in share count from 73.7M to 94.9M plus warrants.

dilution risk

80%

bullishMay 7

Raised $134.6M in February 2026, extending runway through 2028.

capital raise

90%

bearishMay 7

Net loss widened by 39% to $24.2M in the first quarter.

earnings miss

60%

bearishMay 7

Operating cash burn increased 71% year-over-year to $18.9M.

margin compression

70%

bearishMay 7

Significant increase in share count from 73.7M to 94.9M plus warrants.

dilution risk

80%

bullishMay 7

Raised $134.6M in February 2026, extending runway through 2028.

capital raise

90%

bearishMay 7

Net loss widened by 39% to $24.2M in the first quarter.

earnings miss

60%

bearishMay 7

Operating cash burn increased 71% year-over-year to $18.9M.

margin compression

70%

bearishMay 7

Significant increase in share count from 73.7M to 94.9M plus warrants.

dilution risk

80%

bullishMay 7

Raised $134.6M in February 2026, extending runway through 2028.

capital raise

90%

bearishMay 7

Net loss widened by 39% to $24.2M in the first quarter.

earnings miss

60%

bearishMay 7

Operating cash burn increased 71% year-over-year to $18.9M.

margin compression

70%

bearishMay 7

Significant increase in share count from 73.7M to 94.9M plus warrants.

dilution risk

80%

Filing History

8-KMay 22, 2026

Zura Bio has reported the resignation of board member Someit Sidhu, effective May 21, 2026. While the company characterizes the exit as non-contentious, the event highlights the ongoing tension between institutional stability and the risks associated with leadership turnover in small-cap biotech. Investors must weigh the benefit of a clean transition against the potential loss of strategic oversight as the company navigates its clinical and financial runway.

10-QMay 7, 2026

The 10-Q filing reveals a company at a critical juncture, balancing a temporary windfall of capital against a backdrop of escalating expenses. The successful February 2026 equity offering has effectively bought Zura time, shifting the narrative from immediate survival to clinical execution. However, the widening net loss and increased R&D spend highlight the inherent volatility of the biotech model, where capital is consumed rapidly in pursuit of binary clinical outcomes. Ultimately, the filing underscores a high-stakes trade-off for investors. The potential for a value inflection point is immense given the lead asset's dual-antagonist mechanism and the prestige of its licensors. Yet, the looming milestone obligations and the history of rapid dilution create a precarious environment. The market's focus will now shift entirely to the Q4 2026 data readout, as the current cash runway is designed specifically to carry the company through that specific, make-or-break event.